Glaucoma Clinical Trial
— AUREVI 1Official title:
Prospective Pilot Study on the Quantitative Evaluation of Vision Parameters Needed by Virtual Reality Goggle Displays for Subjects With Concentric Visual Field Constriction. AUgmented REality for the Visually Impaired - Part 1
Verified date | May 2016 |
Source | Centre Hospitalier Universitaire de Nimes |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The main objective of this study is to quantify vision parameters in subjects with concentric
visual field constriction, and this in relation to the display on virtual reality goggles.
More specifically:
- The maximum brightness value for visual comfort (THRESHOLD_MAX)
- The minimum value of the perceptible light contrast in low light perceptible
(THRESHOLD_MIN)
- The speed of light change adaptation in the range [THRESHOLD_MAX-THRESHOLD_MIN] and
[THRESHOLD_MIN-THRESHOLD_MAX].
Status | Completed |
Enrollment | 15 |
Est. completion date | May 29, 2017 |
Est. primary completion date | April 20, 2017 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - The patient must have given his/her informed and signed consent - The patient must be insured or beneficiary of a health insurance plan - The subject is suffering from retinitis pigmentosa or glaucoma with concentric visual field constriction and presents with: - An acuity in the better eye superior or equal to 1/10 in near vision, - A binocular field of between 1° and 30°, - A good central fixation, absence of central scotoma, - Motor capability for using a computer keyboard with one hand. Exclusion Criteria: - The patient is participating in another study - The patient is in an exclusion period determined by a previous study - The patient is under judicial protection, or under guardianship - The patient refuses to sign the consent - It is impossible to correctly inform the patient - Subjects with (or evolving toward) a multiple sensory disability, or one including cognitive disorders |
Country | Name | City | State |
---|---|---|---|
France | CHRU de Nîmes - Hôpital Universitaire Carémea | Nîmes Cedex 09 |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire de Nimes |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The maximum brightness value for visual comfort (THRESHOLD_MAX) | 0 to 6 months | ||
Primary | The minimum value of the perceptible light contrast in low light perceptible (THRESHOLD_MIN) | 0 to 6 months | ||
Primary | The speed of light change adaptation within a pre-specified range (getting dimmer) | The pre-specified range goes from THRESHOLD_MAX down to THRESHOLD_MIN. | 0 to 6 months | |
Primary | The speed of light change adaptation within a pre-specified range (getting brighter) | The pre-specified range goes from THRESHOLD_MIN up to THRESHOLD_MAX. | 0 to 6 months | |
Secondary | Optimal range (in degrees) of the visual field provided by the device "RV glasses + camera" | 0 to 6 months | ||
Secondary | Response time in seconds | 0 to 6 months | ||
Secondary | Number of correct responses | 0 to 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06000865 -
Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE
|
N/A | |
Recruiting |
NCT06278597 -
Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device
|
N/A | |
Active, not recruiting |
NCT04271709 -
Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT)
|
N/A | |
Recruiting |
NCT03274024 -
The Asia Primary Tube Versus Trab (TVT) Study
|
N/A | |
Completed |
NCT04552964 -
Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma
|
N/A | |
Recruiting |
NCT01957267 -
Functional and Structural Imaging for Glaucoma
|
||
Active, not recruiting |
NCT04624698 -
iStent Inject New Enrollment Post-Approval Study
|
N/A | |
Completed |
NCT04020705 -
The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma
|
N/A | |
Completed |
NCT03150160 -
Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma
|
Phase 4 | |
Not yet recruiting |
NCT05581498 -
Glaucoma Exercise as Medicine Study (GEMS).
|
N/A | |
Recruiting |
NCT02921568 -
Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes
|
N/A | |
Active, not recruiting |
NCT02901730 -
Clinical Study of LPI With Different Laser Wavelengths
|
N/A | |
Completed |
NCT02955849 -
A Trial of China Laser and Surgery Study Glaucoma in Rural China
|
Early Phase 1 | |
Recruiting |
NCT02471105 -
Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml
|
Phase 4 | |
Recruiting |
NCT02554214 -
Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device
|
N/A | |
Active, not recruiting |
NCT02390284 -
Stop Retinal Ganglion Cell Dysfunction Study
|
Phase 3 | |
Completed |
NCT02653963 -
Triamcinolone for Ahmed Glaucoma Valve
|
N/A | |
Completed |
NCT02520674 -
Glaucoma Screening With Smartphone Ophthalmology
|
N/A | |
Completed |
NCT02246764 -
Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension
|
Phase 3 | |
Completed |
NCT02390245 -
Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study
|
N/A |